Yes...and if that happens....watch its $6B market cap go down the drain! The suits on Wall Street won’t allow that to happen.
Don’t forget, the Patent holders / inventors of Exondys are on the ATL1102 Scientific Advisory Board
As patent holders no doubt they get royalty from Sarepta....you reckon Sue would be putting a few ‘what if?’ scenarios on whiteboard for ANP board re partnership?
If Exondys fails in the US, it will be a setback for everybody, most of all the DMD patients.
So many angles to this story.
How desperate is Sarepta?
Ann: Positive preliminary results from ATL1102 DMD Phase II trial, page-445
-
- There are more pages in this discussion • 151 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.9¢ |
Change
-0.046(34.1%) |
Mkt cap ! $80.23M | |||
| Open | High | Low | Value | Volume |
| 8.7¢ | 9.0¢ | 8.6¢ | $2.082M | 23.82M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 250808 | 8.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.9¢ | 312804 | 3 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| PER (ASX) Chart |